NASDAQ:SRNE

Sorrento Therapeutics Stock Forecast, Price & News

$7.20
+0.19 (+2.71 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.02
$7.33
50-Day Range
$6.93
$9.84
52-Week Range
$2.52
$19.39
Volume4.99 million shs
Average Volume14.21 million shs
Market Capitalization$2.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.7
30 days | 90 days | 365 days | Advanced Chart
Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100
Employees502
Year FoundedN/A

Sales & Book Value

Annual Sales$31.43 million
Book Value$0.20 per share

Profitability

Net Income$-292,070,000.00
Net Margins-698.01%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$2.06 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

See More Headlines
Sorrento Therapeutics logo

About Sorrento Therapeutics

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

766th out of 2,042 stocks

Biological Products, Except Diagnostic Industry

102nd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

Is Sorrento Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sorrento Therapeutics?

Wall Street analysts have given Sorrento Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sorrento Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Sorrento Therapeutics
.

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) issued its earnings results on Friday, February, 19th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The biopharmaceutical company had revenue of $11.51 million for the quarter, compared to analyst estimates of $1.01 billion. Sorrento Therapeutics had a negative net margin of 698.01% and a negative trailing twelve-month return on equity of 314.06%.
View Sorrento Therapeutics' earnings history
.

How has Sorrento Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRNE stock has increased by 289.2% and is now trading at $7.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SRNE?

4 analysts have issued 12-month price targets for Sorrento Therapeutics' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $28.75 in the next twelve months. This suggests a possible upside of 299.3% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 57, Pay $1.19M)
  • Mr. Najjam Asghar, Sr. VP & CFO (Age 39, Pay $351.69k)
  • Mr. Brian Sun, Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. William J. Farley, VP of Sales & Bus. Devel.
  • Dr. Michael A. Royal, SVP & Chief Medical Officer (Age 67)
  • Dr. Alexis Nahama, Sr. VP & Head of RTX Program
  • Dr. Mark R. Brunswick, Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D., Sr. VP of Strategy & Analytics
  • Mr. Brian Cooley, Sr. VP of Lymphatic Drug Delivery BU Leader
  • Dr. Robert D. Allen Ph.D., Sr. VP of Antiviral & Immunotherapy

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Swiss National Bank (0.18%), Alliancebernstein L.P. (0.11%), Rhumbline Advisers (0.10%), Avidian Wealth Solutions LLC (0.07%) and State of New Jersey Common Pension Fund D (0.06%). Company insiders that own Sorrento Therapeutics stock include Kim Janda and Robin L Smith.
View institutional ownership trends for Sorrento Therapeutics
.

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Avidian Wealth Solutions LLC, Rhumbline Advisers, Commonwealth Equity Services LLC, Stratos Wealth Partners LTD., Pacer Advisors Inc., The Manufacturers Life Insurance Company , Cambridge Investment Research Advisors Inc., and Virginia Retirement Systems ET AL.
View insider buying and selling activity for Sorrento Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State of New Jersey Common Pension Fund D, Migdal Insurance & Financial Holdings Ltd., Private Advisor Group LLC, Swiss National Bank, TL Private Wealth, International Assets Investment Management LLC, and Zurcher Kantonalbank Zurich Cantonalbank .
View insider buying and selling activity for Sorrento Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $7.20.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics has a market capitalization of $2.06 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-292,070,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Sorrento Therapeutics have?

Sorrento Therapeutics employs 502 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

Where are Sorrento Therapeutics' headquarters?

Sorrento Therapeutics is headquartered at 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.